Patents-Review.com
ClassID:

20988 ⎘

A61K38/2242 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin

Recent Application in this class:
#1
20260115257
2026-04-30

Dry Pharmaceutical Formulations of CNP Conjugates

 #2
20250381249
2025-12-18

COMBINATION TREATMENT FOR RESISTANT HYPERTENSION

 #3
20250361282
2025-11-27

ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES

 #4
20250195617
2025-06-19

Liquid Pharmaceutical Formulations of CNP Compounds

 #5
20250186553
2025-06-12

Formulations of MANP and Uses Thereof

 #6
20250170217
2025-05-29

C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA IN CHILDREN

 #7
20250127859
2025-04-24

CNP PRODRUGS WITH LARGE CARRIER MOIETIES

 #8
20250073310
2025-03-06

Formulations of MANP and Uses Thereof

 #9
20250032585
2025-01-30

Effective Doses of CNP Conjugates

 #10
20240374688
2024-11-14

Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia

 #11
20240369535
2024-11-07

METHODS AND MATERIALS FOR DETERMINING pGC TARGET DOSAGE

 #12
20240358798
2024-10-31

TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES

 #13
20240316153
2024-09-26

CNP PRODRUGS WITH LARGE CARRIER MOIETIES

 #14
20240269134
2024-08-15

LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HFpEF)

 #15
20240156914
2024-05-16

Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia

 #16
20240041982
2024-02-08

EXTENDED RELEASE HYDROGEL CONJUGATES OF C-NATRIURETIC PEPTIDES

 #17
20230310549
2023-10-05

PREVENTING CYTOKINE RELEASE SYNDROME

 #18
20230293637
2023-09-21

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

 #19
20230233553
2023-07-27

A NEW COMBINATION THERAPY FOR THE TREATMENT OF FGFR3- RELATED SKELETAL DISEASE

 #20
20230173029
2023-06-08

TREATMENT OF CARDIAC REMODELLING

 #21
20230140311
2023-05-04

C-type natriuretic peptide variants to treat skeletal dysplasia in children

 #22
20230128032
2023-04-27

Early Drug Interventions to Reduce COVID-19 Related Respiratory Distress, Need for Respirator Assist and Death

 #23
20230127487
2023-04-27

ASSESSING AND TREATING ACUTE DECOMPENSATED HEART FAILURE

 #24
20230107461
2023-04-06

Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

 #25
20230103704
2023-04-06

HUMAN ANTI-INFLAMMATORY PEPTIDES FOR THE INHALATORY TREATMENT OF INFLAMMATORY PULMONARY ISSUES

 #26
20220362344
2022-11-17

TREATMENT FOR SARS-COV-2 AND OTHER CORONAVIRUSES

 #27
20220296682
2022-09-22

CNP PRODRUGS WITH LARGE CARRIER MOIETIES

 #28
20220249616
2022-08-11

Osteocrin, Lebetin or ANP for Destroying Bacterial Biofilms

 #29
20220160836
2022-05-26

Use of c-type natriuretic peptide variants to treat osteoarthritis

 #30
20220133627
2022-05-05

Stable Therapeutic Formulations

 #31
20220118054
2022-04-21

COMBINATION TREATMENT FOR RESISTANT HYPERTENSION

 #32
20220118053
2022-04-21

Dry Pharmaceutical Formulations of CNP Conjugates

 #33
20210393625
2021-12-23

Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

 #34
20210308224
2021-10-07

Treatment for SARS-CoV-2 and other coronaviruses

 #35
20210283147
2021-09-16

17beta-heterocyclyl-digitalis like compounds for the treatment of heart failure

 #36
20210177942
2021-06-17

CNP prodrugs with large carrier moieties

 #37
20210177840
2021-06-17

Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HFpEF)

 #38
20210139555
2021-05-13

ATRIAL NATRIURETIC PEPTIDE ENGRAFTED ANTIBODIES

 #39
20210077584
2021-03-18

CNP PRODRUGS WITH LARGE CARRIER MOIETIES

 #40
20210040170
2021-02-11

GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE

 #41
20200368324
2020-11-26

Preventing cytokine release syndrome

 #42
20200246434
2020-08-06

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

 #43
20200246433
2020-08-06

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

 #44
20200190511
2020-06-18

MICRO-RNA FAMILY THAT MODULATES FIBROSIS AND USES THEREOF

 #45
20200179488
2020-06-11

Secretin Receptor Agonists to Treat Diseases or Disorders of Energy Homeostasis

 #46
20200115442
2020-04-16

PROTEIN AQUEOUS SUSPENSION PREPARATION

 #47
20190367945
2019-12-05

Method of treating type I diabetes using an AAV vector encoding uracortin 2

 #48
20190270785
2019-09-05

Musclin peptides and methods of use thereof

 #49
20190247467
2019-08-15

Use of C-type natriuretic peptide variants to treat osteoarthritis

 #50
20190056386
2019-02-21

ASSAYS FOR B-TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION

 #51
20190015481
2019-01-17

CNP prodrugs with large carrier moieties

 #52
20180369338
2018-12-27

TREATING CARDIOVASCULAR OR RENAL DISEASES

 #53
20180318397
2018-11-08

Method of treating a vasculopathy in a human subject

 #54
20180318396
2018-11-08

Methods of treating or preventing pruritis by blocking natriuretic polypeptide b

 #55
20180318395
2018-11-08

Method of treating rhinitis with C-type natriuretic peptides

 #56
20180256649
2018-09-13

Stimulation of ovarian follicle development and oocyte maturation

 #57
20180243378
2018-08-30

Treating cardiovascular or renal diseases

 #58
20180207239
2018-07-26

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

 #59
20180194824
2018-07-12

MUSCLIN PEPTIDES AND METHODS OF USE THEREOF

 #60
20180163204
2018-06-14

Micro-RNA family that modulates extracellular matrix genes and uses thereof

 #61
20180099028
2018-04-12

Method for treating dermatitis and improving skin texture using B-type natriuretic peptides

 #62
20180078617
2018-03-22

ANTI-CELL PROLIFERATIVE COMPOUNDS AND METHODS OF USE

 #63
20180010148
2018-01-11

Method of treating type I diabetes using an AAV vector encoding uracortin 2

 #64
20180008675
2018-01-11

USE OF URODILATING FOR PREPARING A MEDICAMENT FOR TREATMENT OF CARDIOVASCULAR, RENAL, PULMONARY, AND NEURONAL SYNDROMES WHILE AVOIDING A REBOUND

 #65
20170348392
2017-12-07

SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES

 #66
20170232072
2017-08-17

Treating cardiovascular or renal diseases

 #67
20170135951
2017-05-18

Stable therapeutic formulations

 #68
20170129934
2017-05-11

Natriuretic polypeptides

 #69
20170051033
2017-02-23

Variants of C-Type Natriuretic Peptide

 #70
20170028023
2017-02-02

Use of C-type natriuretic peptide variants to treat skeletal dysplasia

 #71
20170020899
2017-01-26

ANP fragment adjuvant therapy to standard of care (SOC) diuretic treatment

 #72
20170014486
2017-01-19

Methods of treating or preventing pruritis by blocking natriuretic polypeptide B

 #73
20170007673
2017-01-12

Method for treating rhinitis with B and C-type natriuretic peptide containing chimeric ring structures

 #74
20160375103
2016-12-29

DIURETIC AND NATRIURETIC POLYPEPTIDES

 #75
20160354443
2016-12-08

Replacement Therapy for Natriuretic Peptide Deficiencies

 #76
20160324975
2016-11-10

Reversible pegylated drugs

 #77
20160324931
2016-11-10

Use of Natriuretic Peptide for Treating Heart Failure

 #78
20160324930
2016-11-10

SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES

 #79
20160252528
2016-09-01

Assessing renal structural alterations and outcomes

 #80
20160250293
2016-09-01

Method of treatment dermatitis with c-type natriuretic peptide derivatives

 #81
20160206752
2016-07-21

PROTEIN AQUEOUS SUSPENSION PREPARATION

 #82
20160151460
2016-06-02

Method of treating skeletal dysplasias using vessel dilator

 #83
20160145609
2016-05-26

Micro-RNA family that modulates fibrosis and uses thereof

 #84
20160145608
2016-05-26

Micro-RNA family that modulates fibrosis and uses thereof

 #85
20160145607
2016-05-26

Micro-RNA family that modulates fibrosis and uses thereof

 #86
20160051632
2016-02-25

Chimeric natriuretic peptide compositions and methods of preparation

 #87
20160051631
2016-02-25

Dosage regimen for therapeutic method

 #88
20160017015
2016-01-21

Glyco-modified atrial natriuretic peptide

 #89
20150374793
2015-12-31

Methods of treatment of heart dysfunctions using diuretic and natriuretic polypeptides

 #90
20150299284
2015-10-22

Natriuretic polypeptides

 #91
20150297666
2015-10-22

COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION

 #92
20150293119
2015-10-15

ASSESSING RENAL STRUCTURAL ALTERATIONS AND OUTCOMES

 #93
20150290291
2015-10-15

Solvent/polymer solutions as suspension vehicles

 #94
20150224174
2015-08-13

Use of natriuretic peptide for treating heart failure

 #95
20150203562
2015-07-23

Compounds and methods for modulating pharmacokinetics

 #96
20150190473
2015-07-09

Therapy for kidney disease and/or heart failure

 #97
20150182607
2015-07-02

Use of proteases for gluten intolerance

 #98
20150125457
2015-05-07

BONE REPAIR PROMOTER

 #99
20150080844
2015-03-19

THERAPY FOR KIDNEY DISEASE AND/OR HEART FAILURE BY INTRADERMAL INFUSION

 #100
20150045301
2015-02-12

METHODS AND USES OF ANP (ATRIAL NATRIURETIC PEPTIDE), BNP (BRAIN NATRIURETIC PEPTIDE) AND CNP (C-TYPE NATRIURETIC PEPTIDE)-RELATED PEPTIDES AND DERIVATIVES THEREOF FOR TREATMENT OF RETINAL DISORDERS AND DISEASES

 #101
20150018276
2015-01-15

Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)

 #102
20140357561
2014-12-04

NATRIURETIC POLYPEPTIDE DELIVERY SYSTEMS

 #103
20140314838
2014-10-23

Use of pituitary adenylate cyclase-activating polypeptide (PACAP) and PACAP analogs for treating contrast-induced nephropathy

 #104
20140314762
2014-10-23

Stimulation of ovarian follicle development and oocyte maturation

 #105
20140287999
2014-09-25

Use of natriuretic peptide for treating heart failure

 #106
20140260096
2014-09-18

Stable therapeutic formulations

 #107
20140255518
2014-09-11

Treatment and Prevention of Gastrointestinal Syndrome

 #108
20140248269
2014-09-04

Medicinal agent for preventing exacerbation of malignant tumor, comprising combination of natriuretic peptide receptor GC-A and GC-B agonists

 #109
20140243271
2014-08-28

Method of treating rhinitis with B-type and C-type natriuretic peptides

 #110
20140213520
2014-07-31

METHODS OF TREATING CARDIOVASCULAR INDICATIONS

 #111
20140213519
2014-07-31

METHODS OF TREATING CARDIOVASCULAR INDICATIONS

 #112
20140072557
2014-03-13

MEDICINAL AGENT FOR SUPPRESSING MALIGNANT TUMOR METASTASIS

 #113
20140072520
2014-03-13

Method for treating dermatitis and improving skin texture using natriuretic peptides

 #114
20140066367
2014-03-06

SUBCUTANEOUS DELIVERY OF A LONG-ACTING NATRIURETIC PEPTIDE

 #115
20140030336
2014-01-30

PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ACUTE DISORDERS

 #116
20130324472
2013-12-05

Therapeutic method for treating congestive heart failure

 #117
20130303454
2013-11-14

Method of treating cardiac arrhythmia with long acting atrial natriuretic peptide(LA-ANP)

 #118
20130274207
2013-10-17

Uses of Natriuretic Peptide Constructs

 #119
20130261169
2013-10-03

Micro-RNA family that modulates fibrosis and uses thereof

 #120
20130259908
2013-10-03

Micro-RNA family that modulates fibrosis and uses thereof

 #121
20130195891
2013-08-01

Micro-RNA family that modulates fibrosis and uses thereof

 #122
20130072431
2013-03-21

Cardiovascular therapeutics

 #123
20130064798
2013-03-14

METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE

 #124
20130045928
2013-02-21

Uses of natriuretic peptide constructs

 #125
20130045921
2013-02-21

THERAPEUTIC AGENT FOR RHINITIS

 #126
20130035670
2013-02-07

Solvent/polymer solutions as suspension vehicles

 #127
20130034531
2013-02-07

Use of proteases for gluten intolerance

 #128
20130034210
2013-02-07

Solvent/polymer solutions as suspension vehicles

 #129
20130012439
2013-01-10

Composition for nasal administration and method for preparing same

 #130
20120328699
2012-12-27

METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS

 #131
20120316114
2012-12-13

Variants of C-type natriuretic peptide

 #132
20120315331
2012-12-13

Pharmaceutical composition for the treatment of acute disorders

 #133
20120315330
2012-12-13

Pharmaceutical composition for the treatment of acute disorders

 #134
20120277155
2012-11-01

THERAPY FOR KIDNEY DISEASE AND/OR HEART FAILURE

 #135
20120259318
2012-10-11

Solvent/polymer solutions as suspension vehicles

 #136
20120220528
2012-08-30

SYSTEMS AND METHODS FOR THERAPY OF KIDNEY DISEASE AND/OR HEART FAILURE USING CHIMERIC NATRIURETIC PEPTIDES

 #137
20120220527
2012-08-30

Methods for reducing platelet counts and/or platelet adhesion by administering a GC-B receptor agonist

 #138
20120208756
2012-08-16

COMPOSITION FOR EXTERNAL PREPARATION FOR SKIN

 #139
20120178689
2012-07-12

Methods of treatment of heart failure with natriuretic peptides

 #140
20120164142
2012-06-28

Compositions comprising natriuretic peptides and methods of use thereof

 #141
20120108514
2012-05-03

LONG ACTING ATRIAL NATRIURETIC PEPTIDE (LA-ANP) AND METHODS FOR USE THEREOF

 #142
20110264077
2011-10-27

Solvent/polymer solutions as suspension vehicles

 #143
20110257099
2011-10-20

Use of natriuretic peptide for treating heart failure

 #144
20110256229
2011-10-20

RAPID-ACTING PHARMACEUTICAL COMPOSITION

 #145
20110212068
2011-09-01

METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE

 #146
20110200574
2011-08-18

USE OF PROTEASES FOR GLUTEN INTOLERANCE

 #147
20110152194
2011-06-23

CHIMERIC NATRIURETIC POLYPEPTIDES AND METHODS FOR INHIBITING CARDIAC REMODELING

 #148
20110136739
2011-06-09

Use of S1P Receptor Agonists in Heart Diseases

 #149
20110104111
2011-05-05

Osmotic drug delivery devices containing suspension formulations comprising particles having active agents and nonaqueous single-phase vehicles

 #150
20110039777
2011-02-17

Cancer treatment using natriuretic peptides

 #151
20110034386
2011-02-10

DENDROASPIS NATRIURETIC PEPTIDE FOR TREATMENT OF CANCER

 #152
20110014180
2011-01-20

Preparations for tissue restoration containing atrial diuretic hormone and family molecules as active ingredients; method of restoring tissue using the preparation; agents for growing, restoring, promoting growth of hair and agents for promoting restoration of skin tissue and cardiac muscle tissue containing atrial diuretic hormone family molecules as active ingredients; method of growing, restoring, promoting growth of hair by using the agents; and method of promoting restoration of skin tissue and cardiac muscle tissue

 #153
20100331256
2010-12-30

Variants of C-type natriuretic peptides

 #154
20100297209
2010-11-25

SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES

 #155
20100297021
2010-11-25

Variants of C-type natriuretic peptide

 #156
20100285073
2010-11-11

Micro-RNA family that modulates fibrosis and uses thereof

 #157
20100221229
2010-09-02

Modulating bone growth in treating scoliosis

 #158
20100209958
2010-08-19

Method of screening for an agent for treating arthritis and promoting growth of articular chondrocytes

 #159
20100204446
2010-08-12

Use of natriuretic peptides for treating angioedema syndromes

 #160
20100204114
2010-08-12

USE OF A GALANIN PEPTIDE AS A THERAPEUTIC AGENT

 #161
20100204094
2010-08-12

Diuretic and natriuretic polypeptides lacking the blood pressure lowering property

 #162
20100197588
2010-08-05

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

 #163
20100197586
2010-08-05

USE OF SECRETIN AND OPTIONALLY URODILATIN AS THERAPEUTIC AGENTS

 #164
20100184676
2010-07-22

USE OF A PEPTIDE AS A THERAPEUTIC AGENT

 #165
20100184674
2010-07-22

PROADRENOMEDULLIN ALONE OR IN COMBINATION WITH BIG GASTRIN I AS A THERAPEUTIC AGENT

 #166
20100099602
2010-04-22

PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE FOR THE PREVENTION AND TREATMENT OF HYPOXIC INJURY

 #167
20100055150
2010-03-04

METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS

 #168
20100041867
2010-02-18

Reversible pegylated drugs

 #169
20090317482
2009-12-24

METHODS AND COMPOSITIONS FOR TREATING CONGESTIVE HEART FAILURE

 #170
20090305990
2009-12-10

BI-LATERAL LOCAL RENAL DELIVERY FOR TREATING CONGESTIVE HEART FAILURE AND FOR BNP THERAPY

 #171
20090275512
2009-11-05

COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION

 #172
20090275506
2009-11-05

LONG LASTING NATRIURETIC PEPTIDE DERIVATIVES

 #173
20090238817
2009-09-24

Anti-cell proliferative compounds and methods of use

 #174
20090220507
2009-09-03

INHIBITION OF EXTRACELLULAR SIGNAL-REGULATED KINASE 1/2 AS A TREATMENT FOR CARDIAC HYPERTROPHY AND HEART FAILURE

 #175
20090176706
2009-07-09

Materials and methods for treatment of inflammatory and cell proliferation disorders

 #176
20090170196
2009-07-02

Cancer treatment using C-type natriuretic peptide

 #177
20090163421
2009-06-25

Room Temperature Stable, Lyophilized Natriuretic Peptide Formulations

 #178
20090062206
2009-03-05

Urodilatin Cancer Treatment

 #179
20090029922
2009-01-29

Use of S1P receptor agonists in heart diseases

 #180
20080312142
2008-12-18

Method for increasing body height comprising systemic administration of CNP-53

 #181
20080293632
2008-11-27

Use of natriuretic peptides for the treatment of stature disorders related to shox gene

 #182
20080286368
2008-11-20

Pharmaceutical composition for the treatment of acute disorders

 #183
20080199532
2008-08-21

Long Lasting Natriuretic Peptide Derivatives

 #184
20080194682
2008-08-14

METHOD AND COMPOSITION FOR TREATMENT OF SKELETAL DYSPLASIAS

 #185
20080070858
2008-03-20

Materials and methods for treatment of respiratory allergic diseases

 #186
20080045444
2008-02-21

COMPOSITIONS AND METHODS FOR TREATING CARDIOVASCULAR DISEASE AND MYOCARDIAL INFARCTION WITH DIPEPTIDYL PEPTIDASE INHIBITORS OR B TYPE NATRIURETIC PEPTIDE ANALOGUES RESISTANT TO PROLYL-SPECIFIC DIPEPTIDYL DEGRADATION

 #187
20080039394
2008-02-14

Dendroaspis natriuretic peptide for treatment of cancer

 #188
20080032933
2008-02-07

Type V Phosphodiesterase Inhibitors and Natriuretic Polypeptides

 #189
20070270337
2007-11-22

Pharmaceutical Compositions for Preventing or Treating Th1-Mediated Immune Diseases

 #190
20070197434
2007-08-23

Method of treating arthritis and promoting growth of articular chondrocytes

 #191
20070184096
2007-08-09

Stable therapeutic formulations

 #192
20070172517
2007-07-26

Compositions capable of facilitation penetration across a biological barrier

 #193
20070049521
2007-03-01

Method of use of specific natriuretic peptide receptor c ligands, transgenic non-human mammals expressing specific natriuretic peptide receptor c antagonists and cells thereof

 #194
20070042957
2007-02-22

TYPE V PHOSPHODIESTERASE INHIBITORS AND NATRIURETIC POLYPEPTIDES

 #195
20070031502
2007-02-08

Pharmaceutical composition for the treatment of acute disorders

 #196
20070021358
2007-01-25

Localized delivery of cardiac inotropic agents

 #197
20060280645
2006-12-14

Method for terminal sterilization of transdermal delivery devices

 #198
20060276382
2006-12-07

Materials and methods for treatment of allergic diseases

 #199
20060264376
2006-11-23

Use of natriuretic peptide for treating heart failure

 #200
20060216352
2006-09-28

Rapid-acting pharmaceutical composition

 #201
20060205642
2006-09-14

Oral methods of treatment using proANF peptides

 #202
20060193918
2006-08-31

Solvent/polymer solutions as suspension vehicles

 #203
20060172929
2006-08-03

Use of natriuretic peptides for the treatment of stature disorders related to the shox gene

 #204
20060171920
2006-08-03

Reversible pegylated drugs

 #205
20060140916
2006-06-29

Methods and compositions for treating congestive heart failure

 #206
20060067972
2006-03-30

Devices for renal-based heart failure treatment

 #207
20060034903
2006-02-16

Apparatus and method for transdermal delivery of natriuretic peptides

 #208
20060025367
2006-02-02

Adenovirus vectors encoding brain natriuretic peptide

 #209
20060019890
2006-01-26

Method for treating cardiac remodeling following myocardial injury

 #210
20060014689
2006-01-19

Method of treatment of cancer using guanosine 3′, 5′ cyclic monophosphate (cyclic GMP)

 #211
20050272650
2005-12-08

Materials and methods for treatment of inflammatory and cell proliferation disorders

 #212
20050267010
2005-12-01

Bi-lateral local renal delivery for treating congestive heart failure and for BNP therapy

 #213
20050222092
2005-10-06

Use of s1p receptor agonists in heart diseases

 #214
20050209139
2005-09-22

Cancer treatment using C-type natriuretic peptides

 #215
20050181066
2005-08-18

Novel use of guanylate cyclase activators for the treatment of respiratory insufficiency

 #216
20050176641
2005-08-11

Long lasting natriuretic peptide derivatives

 #217
20050148024
2005-07-07

Methods and compositions for measuring natriuretic peptides and uses thereof

 #218
20050113286
2005-05-26

Methods for treating congestive heart failure

 #219
20050089514
2005-04-28

Use of natriuretic peptides as antibiotically active substances for the treatment of bacterial infections